Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416556 | 0.86 | TYR (0.49) | MAOBCYP1A2TBXAS1LMNAUSP2 | |
| SCHEMBL23285244 | 0.85 | MAOB (0.56) | MAOBGPR183CYP1A2TBXAS1LMNA | |
| SCHEMBL5201692 | 0.84 | CYP24A1 (0.54) | CYP1A2TBXAS1LMNAUSP2MEN1 | |
| SCHEMBL1186024 | 0.84 | CYP24A1 (0.54) | CYP1A2TBXAS1LMNAUSP2MEN1 | |
| SCHEMBL16765774 | 0.81 | CYP1A2 (0.55) | GPR183CYP1A2MEN1CYP3A4CYP2D6 | |
| SCHEMBL14375119 | 0.81 | CYP1A2 (0.55) | GPR183CYP1A2MEN1CYP3A4CYP2D6 | |
| SCHEMBL3363375 | 0.81 | HSD17B3 (0.54) | MAOBGPR183CYP1A2TBXAS1MEN1 | |
| SCHEMBL21181012 | 0.81 | MAOB (0.59) | MAOBCYP1A2TBXAS1LMNAUSP2 | |
| SCHEMBL6270359 | 0.79 | ACHE (0.52) | LMNAMEN1CYP3A4KMT2AMAPT | |
| SCHEMBL18374565 | 0.78 | CYP24A1 (0.46) | MAOBCYP1A2TBXAS1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | disclosed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | disclosed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | PPP3CA, PTPA, PPP3CB | MAOB 157/4885CYP17A1 1671/4885CYP21A2 1389/4885 |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | MAOB 1355/4885CYP17A1 292/4885CYP21A2 98/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | MAOB 723/4885CYP17A1 502/4885CYP21A2 240/4885 |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | MAOB 530/4885CYP17A1 229/4885CYP21A2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.